![Emil Kakkis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Emil Kakkis
Oprichter bij
ULTRAGENYX PHARMACEUTICAL INC.
Vermogen: 90 M $ op 30-06-2026
Profiel
Emil D. Kakkis richtte Ultragenyx Pharmaceutical, Inc. en Everylife Foundation for Rare Diseases op. Dr. Kakkis bekleedt de functie van President, Chief Executive Officer & Director bij Ultragenyx Pharmaceutical, Inc. Dr. Kakkis zit ook in de raad van bestuur van Emil Kakkis & Jenny Soriano Living Trust en Odylia Therapeutics en is voorzitter van Everylife Foundation for Rare Diseases. In zijn vorige carrière was Dr. Kakkis Chief Medical Officer & Senior Vice President voor BioMarin Pharmaceutical, Inc. en assistent professor aan het Harbor-UCLA Medical Center. Dr. Kakkis behaalde een doctoraat aan het Pomona College en een doctoraat aan de David Geffen School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-04-2026 | 2.694.724 ( 2,74% ) | 90 M $ | 30-06-2026 |
Laatste nieuws over Emil Kakkis
Actieve functies van Emil Kakkis
| Bedrijven | Functie | Begin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Oprichter | 22-04-2010 |
Emil Kakkis & Jenny Soriano Living Trust | Directeur/Bestuurslid | - |
Everylife Foundation for Rare Diseases
 Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization, which dedicates to accelerating rare disease treatments | Oprichter | 01-03-2009 |
Odylia Therapeutics
 Odylia Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit biotech that develops therapies for rare diseases | Directeur/Bestuurslid | 01-01-2019 |
Eerdere bekende functies van Emil Kakkis
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Hoofd Techniek/Wetenschap/O&O | 27-02-2009 |
Harbor-UCLA Medical Center
 Harbor-UCLA Medical Center Medical/Nursing ServicesHealth Services Provides medical practice, education and research services | Corporate Officer/Principal | 01-01-1998 |
Opleiding van Emil Kakkis
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
67
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Pomona College
 Pomona College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
David Geffen School of Medicine
 David Geffen School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harbor-UCLA Medical Center
Harbor-UCLA Medical Center Medical/Nursing ServicesHealth Services Provides medical practice, education and research services | Health Services |
Emil Kakkis & Jenny Soriano Living Trust | |
Everylife Foundation for Rare Diseases
Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization, which dedicates to accelerating rare disease treatments | Commercial Services |
Odylia Therapeutics
Odylia Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit biotech that develops therapies for rare diseases | Commercial Services |
Kies MarketScreener 
